Efficiency and safety of the fixed latanoprost/ dorzolamide combination in open-angle glaucoma hypotensive treatment

Purpose: to determine the efficacy and safety of fixed latanoprost/dorzolamide combination Dorzoprost in hypotensive treatment of primary open-angle glaucoma (POAG) patients previously treated with latanoprost.
Material and methods. An observational study included 30 patients (37 eyes) with moderate and advanced POAG who had uncompensated elevated IOP receiving latanoprost monotherapy. During the screening visit, latanoprost was switched to Dorzoprost instilled once in the evening. The targets were IOP, visual acuity, MD and PSD perimetry indices, retinal nerve fiber layer thickness, minimum width of the neuroretinal rim, macula retinal nerve fiber layer thickness, and adverse events. The observation period lasted 12 weeks. IOP was measured at weeks 4 and 12.
Results. After 4 weeks, a statistically significant decrease in IOP was noted, which remained stable at 12 weeks. The average additional IOP decrease of those treated with Dorzoprost was 17%. Statistically insignificant positive changes were registered in visual acuity, static perimetry and optical coherence tomography. By the end of the observation period, 6 cases revealed a decrease in the degree of conjunctival hyperemia, while all dry eye syndrome cases (5 patients) showed a decrease in the severity of the signs of the syndrome.
Conclusion. Dorzoprost has a significant additive hypotensive effect and a favorable safety profile.

1. Neroev V.V., Kiseleva O.A., Bessmertny A.M. The main results of a multicenter study of epidemiological features of primary open-angle glaucoma in the Russian Federation. Russian ophthalmological journal. 2013; 6 (3): 4–7 (In Russ.).

2. Tham YC, Li ., Wong TY, Quigley H., Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–2090. doi:10.1016/j.ophtha.2014.05.013

3. Neroev V.V., Mikhailova L.A. Ophthalmic morbidity in Russia. In: Avetisov S.E., Egorov E.A., Moshetova L.K., Takhchidi Kh.P., eds. Ophthalmology. National Giidelines. Moscow: GEOTAR-Media, 2018: 15–9 (In Russ.).

4. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991; 134 (10): 1102–10. doi:10.1093/oxfordjournals.aje.a116013

5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90 (3): 262–7. doi:10.1136/bjo.2005.081224

6. Sotimehin AE, Ramulu PY. Measuring disability in glaucoma. J Glaucoma. 2018; 27 (11): 939–49. doi:10.1097/IJG.0000000000001068

7. Statistical compilation of the Department for monitoring analysis and strategic development of health care of the Federal State Budgetary Institution “TsNIIOIZ” of the Ministry of Health of Russia “General incidence of the adult population of Russia in 2022”. Available at: https://rosstat.gov.ru/folder/210/document/13218 (In Russ.).

8. Peters D, Bengtsson B, Heijl A. Factors associated with lifetime risk of openangle glaucoma blindness. Acta Ophthalmol. 2014; 92 (5): 421–5. doi:10.1111/aos.12203

9. Clinical Gidelines «Primary open angle glaucoma». 2020 (16.02.2021), Approved by the Ministry of Health of the Russian Federation (In Russ). Available at: http://avo-portal.ru/documents/fkr/Klinicheskie_rekomendacii_POUG_2022.pdf.

10. Hommer A, Hubatsch DA, Cano-Parra J. Safety and efficacy of adding fixedcombination Brinzolamide/Timolol Maleate to prostaglandin therapy for treatment of ocular hypertension or glaucoma. J Ophthalmol. 2015; 131970. doi:10.1155/2015/131970

11. Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011; 5: 291–8. doi:10.2147/OPTH.S16355

12. Lorenz K, Rosbach K, Matt A, Pfeiffer N. Addition of a fixed combination of brinzolamide 1% / timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension. Clin Ophthalmol. 2011; 5: 1745–1750. doi:10.2147/OPTH.S25987

13. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008; 25 (9): 729–59. doi:10.2165/00002512-200825090-00002

14. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008; 25 (9): 729–59. doi:10.2165/00002512-200825090-00002

15. Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressurelowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014; 15 (12): 1737–47. doi:10.1517/14656566.2014.936850

16. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. Journal of glaucoma. 2009; 18 (3): 238–43. doi:10.1097/IJG.0b013e3181815421

17. Taylor SA, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2002; 18 (5): 401–9. doi:10.1089/10807680260362687

18. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995 May-Jun; 26 (3): 233–6. PMID: 7651690.

19. Dunker S, Schmucker A, Maier H. Latanoprost/Timolol Fixed Combination Study Group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007 Mar-Apr; 24 (2): 376–86. doi: 10.1007/BF02849907

20. Heijl A, Traverso CE, eds. Terminology and Guidelines for Glaucoma. European Glaucoma Society. 4th ed. Savona, Italy: PubliComm; 2014: 146–51. Available at: www.eugs.org/eng/EGS_guidelines4.asp

21. Konstas AG, Hollo G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J of ophthalmol. 2010; 94 (2): 209–13. doi:10.1136/bjo.2008.155317

22. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I. Ganfort Investigators G, II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. Journal of glaucoma. 2008; 17 (3): 211–6. doi:10.1097/IJG.0b013e3181507313

23. Zhuravleva A.N., Zueva M.V., Shustov E.B. Optimization of medicinal treatment of patients with glaucoma in combination with concurrent system pathology. Part 1: Cardiovascular pathology. Ophthalmology in Russia. 2020; 17 (3): 321–9 (In Russ.). doi:10.18008/1816-5095-2020-3-321-329

24. Instruction for Timolol-SOLOpharm medical using (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e879f1bb-52a5-4917-9e11-2cb8cde1e56e (date of the application: 19.08.2023).

25. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidencebased assessment. Am J Ophthalmol. 2002; 134 (5): 749–760. doi: 10.1016/s0002-9394(02)01699-9

26. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984; 102 (7): 601–4. doi: 10.1001/archopht.1984.01040030429017

27. Williamson J, Young JD, Atta H, Muir J, Kadom H. Comparative efficacy of orally and topically administered beta-blockers for chronic simple glaucoma. Br J Ophthalmol. 1985; 69 (1): 41-5. doi:10.1136/bjo.69.1.41

28. Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Advances in therapy. 2014; 31 (12): 1213–27. doi:10.1007/s12325-014-0168-y

29. Инструкция по медицинскому примененению препарата Дорзопрост. [Instruction for Dorzoprost medical using (In Russ.). Available at: https:// grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=afd49d9f-5b1b-4faaa181-6dda2e6c0a0e (date of the application: 19.08.2023).

30. Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary openangle glaucoma subjects. Ophthalmology. 2005; 112 (4): 603–8. doi:10.1016/j.ophtha.2004.11.032

31. Tamer C, Oksuz H. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Ophthalmic Res. 2007; 39 (1): 24–31. doi:10.1159/000097903

32. Bournias TE, Lai J. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. Ophthalmology. 2009; 116 (9): 1719–24. doi:10.1016/j.ophtha.2009.03.050

33. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. J Glaucoma. 2006; 15 (4): 341–5. doi: 10.1097/01.ijg.0000212240.11219.49

34. Tsukamoto H, Noma H, Matsuyama S, Ikeda H, Mishima HK. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005; 21 (2): 170–3. doi:10.1089/jop.2005.21.170

35. Domagk G. Eine neue Klasse von Desinfectionsmitteln. Deutsche Medizin Wissenschafter. 1935; 61: 829–32. doi:10.1055/s-0028-1129654

36. Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998; 82 (1): 39–42. doi: 10.1136/bjo.82.1.39

37. Chung SH, Lee SK, Cristol SM, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis. 2006 Apr 26; 12: 415–21. PMID: 16688112

38. Baudouin C. A new approach for better comprehension of diseases of the ocular surface. J Fr Ophtalmol. 2007; 30 (3): 239–46. doi:10.1016/s0181-5512(07)89584-2

39. Krishna N, Brow F. Polyvinyl alcohol as an ophthalmic vehicle. Effect on regeneration of corneal epithelium. Am J Ophthalmol. 1964; 57: 99–106. doi:10.1016/0002-9394(64)92038-0